The estimated Net Worth of Martin J. Madden is at least $422 Thousand dollars as of 5 August 2021. Mr. Madden owns over 34 units of NovoCure Ltd stock worth over $6,616 and over the last 7 years he sold NVCR stock worth over $5,206. In addition, he makes $409,970 as Independent Director at NovoCure Ltd.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Madden NVCR stock SEC Form 4 insiders trading
Martin has made over 2 trades of the NovoCure Ltd stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 34 units of NVCR stock worth $5,206 on 5 August 2021.
The largest trade he's ever made was exercising 8,906 units of NovoCure Ltd stock on 21 May 2019 worth over $435,236. On average, Martin trades about 497 units every 45 days since 2017. As of 5 August 2021 he still owns at least 384 units of NovoCure Ltd stock.
You can see the complete history of Mr. Madden stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Martin Madden biography
Martin J. Madden serves as Independent Director of the Company. Mr. Madden recently retired after a 30-year career at Johnson & Johnson (1986 to January 2017), where he most recently served as Vice President Research and Development DePuy-Synthes and Vice President Medical Device R&D Transformation from February 2016 to January 2017, as Vice President New Product Development, Medical Devices from July 2015 to February 2016, and as Vice President R&D Global Surgery Group from January 2012 to July 2015. Earlier in his career, Mr. Madden was a medical device engineer and innovator, and a leader of cross-functional teams charged with incubating, developing, and launching new products. He has been Director of Microbot Medical Inc. since 2017; former director of TSO3, Inc. (acquired by Stryker Corporation) (2018- 2019). He holds M.B.A. with Honors, Columbia University; Masters degree with honors in Mechanical Engineering, Carnegie-Mellon University; Bachelor’s degree in Mechanical Engineering, summa cum laude, University of Dayton.
What is the salary of Martin Madden?
As the Independent Director of NovoCure Ltd, the total compensation of Martin Madden at NovoCure Ltd is $409,970. There are 13 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.
How old is Martin Madden?
Martin Madden is 58, he's been the Independent Director of NovoCure Ltd since 2017. There are 13 older and 10 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.
What's Martin Madden's mailing address?
Martin's mailing address filed with the SEC is C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE, PA, 19087.
Insiders trading at NovoCure Ltd
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ..., and Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
What does NovoCure Ltd do?
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
What does NovoCure Ltd's logo look like?
Complete history of Mr. Madden stock trades at Microbot Medical Inc and NovoCure Ltd
NovoCure Ltd executives and stock owners
NovoCure Ltd executives and other stock owners filed with the SEC include:
-
William Doyle,
Executive Chairman of the Board -
Asaf Danziger,
President, Chief Executive Officer, Director -
Michael Ambrogi,
Vice President - Senior Technology Fellow -
Wilhelmus Groenhuysen,
Chief Operating Officer -
Pritesh Shah,
Chief Commercial Officer -
Asaf Danziger,
Pres, CEO & Director -
William F. Doyle,
Exec. Chairman -
Wilhelmus C. M. Groenhuysen,
Chief Operating Officer -
Todd C. Longsworth,
Gen. Counsel -
Ashley Cordova,
CFO & VP of Investor Relations -
Pritesh Shah,
Chief Commercial Officer -
William Vernon,
Lead Independent Director -
Jeryl Hilleman,
Independent Director -
Martin Madden,
Independent Director -
Sherilyn McCoy,
Independent Director -
David Hung,
Independent Director -
Kinyip Gabriel Leung,
Independent Director -
Frank Leonard,
Chief Development Officer -
Todd Longsworth,
General Counsel -
Ely Benaim,
Chief Medical Officer -
Ashley Cordova,
Chief Financial Officer -
Dr. Ely Benaim M.D.,
Chief Medical Officer -
Barak Ben Arye,
Gen. Counsel -
Ingrid Goldberg,
VP of Investor Relations -
Prof. Yoram Palti M.D., Ph.D.,
Founder & CTO -
Uri Weinberg M.D., Ph.D.,
Chief Science Officer -
Dr. Ely Benaim,
Chief Medical Officer -
William Patrick Burke,
Chief HR Officer -
Prof. Yoram Palti,
Founder & CTO -
Timothy J Scannell,
-
Eilon D. Kirson,
Chief Scientific Officer -
Gert L.Volati Ltd Perlhagen,
-
Peter M. Melnyk,
Chief Commercial Officer -
Yoram Palti,
Chief Technology Officer -
Charles G Iii Phillips,
Director -
Louis J Jr Lavigne,
Director -
Ltd Volati,
10% owner -
William Fwfd Ventures Fund ...,
-
Gert L. Perlhagen,
Director -
William T. Burkoth,
Director -
Capital Vii, L.P.Pomona Cap...,
-
Moshe Giladi,
Chief Science Officer -
Nicolas Leupin,
Chief Medical Officer -
Robert J Jr Mylod,
Director -
Timothy J. Langloss,
Director -
Hansjoerg Wyss,
10% owner -
Allyson J Ocean,
-
William Patrick Burke,
Chief Human Resources Officer -
Uri Weinberg,
Chief Innovation Officer -
W Anthony Vernon,
-
Kristin Stafford,
-
Gabriel Leung,
-
Arye Barak Ben,
General Counsel -
Michal Nath Puri,
Chief Human Resources Officer